Life science entrepreneur and private investor Brian Frenzel has extensive experience founding and growing startups and guiding them to successful exits for investors. Drawing on his deep knowledge of biotechnology and biopharmaceuticals, Brian Frenzel is the CEO of Tosk, Inc. Tosk’s mission is to improve outcomes for cancer patients by eliminating the dose-limiting, often debilitating, and potentially fatal adverse effects of cancer therapies and to make certain therapies effective in patients who currently do not benefit from treatment. One of these drugs is TK-90, which recently completed the first phase of human clinical trials. TK-90 is designed to protect against the mucositis triggered by certain cancer therapies and antibiotics. Mucositis is caused by inflammation in the gastrointestinal tract and can result in painful ulcers in the mouth and throughout the GI tract. Mucositis can open a route of infection that can be dangerous for immune-compromised patients. Mucositis can also limit the dosing of certain cancer drugs to less than would otherwise be desirable. TK-90 has now entered the second phase of testing in head and neck cancer patients. This phase is designed to determine the optimal dose of TK-90 and to further demonstrate both the safety and efficacy of the drug.
16 Comments
|
AuthorAt Genelabs Technologies in the 1980’s, Brian Frenzel served on the front lines in the war on HIV/AIDS and championed projects to identify and diagnose new hepatitis viruses. Archives
June 2020
Categories
All
|